Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.9.3595

Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma  

Wang, Chun-Hsiang (Department of Hepatogastroenterology, Tainan Municipal Hospital)
Wey, Keh-Cherng (Department of Hepatogastroenterology, Tainan Municipal Hospital)
Mo, Lein-Ray (Department of Hepatogastroenterology, Tainan Municipal Hospital)
Chang, Kuo-Kwan (Department of Hepatogastroenterology, Tainan Municipal Hospital)
Lin, Ruey-Chang (Department of Hepatogastroenterology, Tainan Municipal Hospital)
Kuo, Jen-Juan (Department of Hepatogastroenterology, Tainan Municipal Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.9, 2015 , pp. 3595-3604 More about this Journal
Abstract
Hepatocellular carcinoma (HCC) has been one of the most fatal malignant tumors worldwide and its associated morbidity and mortality remain of significant concern. Based on in-depth reviews of serological diagnosis of HCC, in addition to AFP, there are other biomarkers: Lens culinaris agglutinin-reactive AFP (AFP-L3), descarboxyprothrombin (DCP), tyrosine kinase with Ig and eprdermal growth factor (EGF) homology domains 2 (TIE2)-espressing monocytes (TEMs), glypican-3 (GPC3), Golgi protein 73 (GP73), interleukin-6 (IL-6), and squamous cell carcinoma antigen (SCCA) have been proposed as biomarkers for the early detection of HCC. The diagnosis of HCC is primarily based on noninvasive standard imaging methods, such as ultrasound (US), dynamic multiphasic multidetector-row CT (MDCT) and magnetic resonance imaging (MRI). Some experts advocate gadolinium diethyl-enetriamine pentaacetic acid (Gd-EOB-DTPA) MRI and contrast-enhanced US as the promising imaging madalities of choice. With regard to recent advancements in tissue markers, many cuting-edge technologies using genome-wide DNA microarrays, qRT-PCR, and proteomic and inmunostaining studies have been implemented in an attempt to identify markers for early diagnosis of HCC. Only less than half of HCC patients at initial diagnosis are at an early stage treatable with curative options: local ablation, surgical resection, or liver transplant. Transarterial chemoembolization (TACE) is considered the standard of care with palliation for intermediate stage HCC. Recent innovative procedures using drug-eluting-beads and radioembolization using Yttrium-90 may exhibit beneficial effects in HCC treatment. During the past few years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. Sorafenib is currently the only approved systemic treatment for HCC. It has been approved for the therapy of asymptomatic HCC patients with well-preserved liver function who are not candidates for potentially curative treatments, such as surgical resection or liver transplantation. In the USA, Europe and particularly Japan, hepatitis C virus (HCV) related HCC accounts for most liver cancer, as compared with Asia-Pacific regions, where hepatitis B virus (HBV) may play a more important role in HCC development. HBV vaccination, while a vaccine is not yet available against HCV, has been recognized as a best primary prevention method for HBV-related HCC, although in patients already infected with HBV or HCV, secondary prevention with antiviral therapy is still a reasonable strategy. In addition to HBV and HCV, attention should be paid to other relevant HCC risk factors, including nonalcoholic fatty liver disease due to obesity and diabetes, heavy alcohol consumption, and prolonged aflatoxin exposure. Interestingly, coffee and vitamin K2 have been proven to provide protective effects against HCC. Regarding tertiary prevention of HCC recurrence after surgical resection, addition of antiviral treatment has proven to be a rational strategy.
Keywords
Hepatocellular carcinoma; hepatitis B virus; hepatitis C virus; transarterial chemoembolization;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Andea L, Isgro G, Pleguezueli M et al (2009). Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol, 1, 48-61.   DOI
2 Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994). Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology, 107, 1103-9.
3 Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P (2000). Molecular basis for the development of the hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol, 10, 211-31.   DOI
4 Burrel M, Llovet JM, Ayuso C, et al (2003). MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatol, 38, 1034-2.   DOI
5 Chang MH, Chen TH, Hsu HM, (2005). Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res, 11, 7953-7   DOI
6 Cuadrado A, Orive A, Garcia-Suarez C, et al (2005). Nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg, 15, 442-6.   DOI
7 Chen CL, Yang HI, Yang WS, et al (2008). Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterol, 135, 111-21.   DOI
8 Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34.   DOI
9 Chang MH, You SL, Chen CJ, et al (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst, 101, 1348-5.   DOI
10 Cohn A, Kelley RK, Yang TS, et al (2012). Activity of cabozantinib (XL184) in hepatocellular carcinoma patients: results from a phase II randomized discontinuation trial (RDT), J Clin Oncol, 30, 4007.
11 Donato F, Tagger A, Gelatti U, et al (2002). Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol, 155, 323-1.   DOI
12 Di Bisceglie AM, Sterling, RK, Chung RT, et al (2005). Serum ${\alpha}$-fetoprotein levels in patients with advanced hepatitis : results from the HALT-C Trial. J Hepatol, 43, 434-1.   DOI
13 Di Tommaso L, Franchi G, Park YN, et al (2007). Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatol, 45, 725-4.   DOI
14 Hosaka T, Suzuki F, Kobayashi M, et al (2013). Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatol, 58, 98-7.
15 Hsia CY, Huo TI, Chiang SY, et al (2007). Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol, 33, 208-2.   DOI
16 Hilgard P, Hamami M, Fouly AE, et al (2010). Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatol, 52, 1741-9.   DOI
17 Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY (2013). Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol, 58, 150-7.   DOI   ScienceOn
18 International Consensus Group for Hepatocellular Neoplasia (2009). Pathological diagnosis of early hepatocellular carcinoma: a report of the international concensus group for hepatocellular neoplasia. Hepatol, 49, 658-4.   DOI
19 Ichikawa T, Sano K, Morisaka H (2014). Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus. Liver Cancer, 3, 97-107.   DOI
20 Joo I, Choi BI. (2012). New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer, 1, 94-9.   DOI
21 Koike Y, Shiratori Y, Sato S, et al (2001). Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer, 91, 561-9.   DOI
22 Lok AS, Everhart JE, Wright EC, et al (2011). Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterol, 140, 840-9.   DOI   ScienceOn
23 Llovet JM, Ricci S, Mazzaferro V, et al (2008). SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90.   DOI
24 Lok AS, Sterling RK, Everhart JE, et al (2010). Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterol, 138, 493-2.   DOI
25 Lencioni R, Zou J, Leberre M, et al (2010). Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). J Clin Oncol, 28, 15.   DOI
26 Lok AS, Gardiner DF, Lawitz E. et al (2012). Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med, 366, 216-4.   DOI   ScienceOn
27 Lee JM, Yoon JH, Joo I, Woo HS (2012). Recent advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer, 1, 22-40.   DOI
28 Lin IY, Yen CH, Liao YJ, et al (2013). Identification of FKBP11 as a biomarker for hepatocellular carcinoma. Anticancer Res, 33, 2763-9.
29 Llovet JM, Decaens T, Raoul JL, et al (2013). Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol, 31, 3509-6.   DOI
30 Mazzaferro V, Regalia E, Doci R, et al (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 334, 693-9.   DOI
31 Nakazawa T, Hidaka H, Shibuya A, et al (2014). Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol, 14, 84-90.   DOI
32 Murakami T, Tsurusaki M (2014). Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer, 3, 85-96.   DOI
33 Ng KK, Vauthey JN, Pawlik TM, et al (2005). Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol, 12, 364-3.   DOI
34 NCCN Clinical Practical Guidances in Hepatobiliary Cancers, 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed
35 Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.   DOI
36 Pawlik TM, Poon RT, Abdalla EK, et al (2005). Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery, 137, 403-10.   DOI
37 Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A (2010). Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t)ide therapy: a systematic review. J Hepatol, 53, 348-6.   DOI   ScienceOn
38 Park MJ, Kim YK, Lee MW, et al (2012). Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiol, 264, 761-70.   DOI
39 Park JW, Koh YH, Kim HB, et al (2012). Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol, 56, 1336-2.   DOI   ScienceOn
40 Wang CH, Chang KH (2012). Long-term assessment of hepaticellular carcinoma riask in chronic hepatitis C patients with sustained viral response to antiviral treatment. Gastroenterol, 142, 1060.   DOI
41 Wu CY, Chen YJ, Ho HJ, et al (2012). Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA, 308, 1906-4.   DOI
42 Wong GLH, Wong VWS (2013). Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol, 19, 6515-2.   DOI
43 Xie H, Ma H, Zhou D (2013). Plasma HULC as a Promising Novel Biomarker for the Detection of Hepatocellular Carcinoma. Biomed Res Int, 2013, 136106.
44 Yoshizawa H (2002). Hepatocellular carcinoma associated with hepa- titis C virus infection in Japan: projection to other countries in the foreseeable future. Oncol, 62, 8-17.   DOI
45 Yoshizawa H, Tanaka J, Miyakawa Y (2006). National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology, 49, 7-17.   DOI
46 Yuen MF, Tanaka Y, Fong DY, et al (2009). Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol, 50, 80-8.   DOI
47 Yang HI, Yuen MF, Chan HL, et al (2011). Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol, 12, 568-4.   DOI
48 Yu NC, Chaudhari V, Raman SS, et al (2011). CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol, 9, 161-7.   DOI
49 Bruix J, Sherman M (2011). American association for the study of liver diseases management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2.   DOI
50 Bravi F, Bosetti C, Tavani A, et al (2007). Coffee drinking and hepatocellular carcinoma risk: a meta- analysis. Hepatol, 46, 430-5.   DOI
51 Bruix J, Tak WY, Gasbarrini A, et al (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer, 49, 3412-9.   DOI
52 Chen HL, Chang MH, Ni YH, et al (1996). Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA, 276, 906-8.   DOI
53 Chang MH, Chen CJ, Lai MS, et al (1997). For the Taiwan childhood hepatoma study group. universal hepatitis b vaccination in taiwan and the incidence of hepatocellular carcinoma in Children. N Engl J Med, 336, 1855-9.   DOI
54 Caldwell SH, Oelsner DH, Iezzoni JC, et al (1999). Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatol, 29, 664-9.   DOI
55 Chang MH, Shau WY, Chen CJ, et al (2000). Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA, 284, 3040-2.   DOI
56 Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterol, 125, 89-7.   DOI
57 Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterol, 125, 89-97.   DOI
58 El-Serag HB (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology,142, 1264-3.   DOI   ScienceOn
59 Dohmen K, Kawano A, Takahashi K, et al (2013). The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Hepatogastroenterol, 60, 2034-8.
60 Dhayat SA, Mardin WA, Kohler G, et al (2014). The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol, in press.
61 Franca AVC, junior, LE, Lima BLG, Martinelli ALC, Carrilho, FL (2004). Diagnosis, staging and treatment of hepatoceelualr carcinoma. Brazilian Journal of Medical and Biological Research, 37, 1689-705.
62 Franceschi S, Montella M, Polesel J, et al (2006). Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev, 15, 683-9.   DOI
63 Forner A, Vilana R, Ayuso C, et al (2008). Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology, 47, 97-4.
64 Giannelli G, Marinosci F, Trerotoli P, et al (2005). SCCA antigen combined with ${\alpha}$-fetoprotein as serologic markers of HCC. Int J Cancer, 117, 506-9.   DOI
65 Hsu HM, Chen DS, Chuang CH, et al (1988). Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA, 260, 2231-5.   DOI
66 Habu D, Shiomi S, Tamori A, et al (2004). Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA, 292, 358-1.   DOI
67 Llovet JM, Fuster J, Bruix J (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatol, 30, 1434-40.   DOI
68 Kudo M, Imanaka K, Chida N, et al (2011). Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer, 47, 2117-27.   DOI   ScienceOn
69 Kudo M, Han G, finn RS, et al (2014). Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase 3 trial. Hepatol, 60, 1697-7.   DOI
70 Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-8.   DOI
71 Lim SG, Mohammed R, Yuen MF, Kao JH (2009). Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol, 24, 1352-7.   DOI
72 Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatol, 37, 429-42.   DOI
73 Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004). Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol, 10, 2878-2.   DOI
74 Llovet JM, Chen Y, Wurmbach E, et al (2006). A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterol, 31, 1758-7.
75 Larsson SC, Wolk A (2007). Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology, 132, 1740-5.   DOI
76 Mazzaferro V, Romito R, Schiavo M, et al (2006). HCC Italian task force. prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatol, 44, 1543-54.   DOI
77 Matteoni CA, Younossi ZM, Gramlich T, et al (1999). Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol, 116, 1413-9.   DOI
78 Marrero JA, Su GL, Wei W, et al (2003). Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatol, 37, 1114-1.   DOI
79 Marrero JA, Romano PR, Nikolaeva O, et al (2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 43, 1007-2.   DOI   ScienceOn
80 Masuzaki R, Yoshida H, Omata M (2010). Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros Dig Liver Dis, 42, 281-6.   DOI
81 Malagari K, Pomoni M, Kelekis A, et al (2010). Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol, 33, 541-51.   DOI
82 Morgan RL, Baack B, Smith BD, et al (2013). Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med, 158, 329-7.   DOI   ScienceOn
83 Matsubara T, Kanto T, Kuroda S, et al (2013). TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatol, 57, 1416-5.   DOI
84 Michelotti GA, Machado MV, Diehl AM (2013). NAflD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol, 10, 656-5.   DOI
85 Shiina S, Teratani T, Obi S, et al (2005). A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterol, 129, 122-30.   DOI
86 Qi J, Wang J, Katayama H, Sen S, Liu SM (2013). Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma, 60, 135-2.
87 Roskams T, Kojiro M (2010). Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis, 30, 17-25.   DOI
88 Sakai I, Hashimoto S, Yoda M, et al (1994). Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun, 205, 1305-10.   DOI
89 Sterling RK, Jeffers L, Gordon F, et al (2007). Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol, 102, 2196-5.   DOI
90 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, et al (2009). Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther, 30, 37-47.   DOI
91 Salem R, Lewandowski RJ, Mulcahy MF, et al (2010). Radioembolization for hepatocellular carcinoma using Yttrium-90 micro- spheres: a comprehensive report of longterm outcomes. Gastroenterology, 138, 52-64.   DOI
92 Sano K, Ichikawa T, Motosugi U, et al (2011). Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology, 261, 834-4.   DOI
93 Tsai SL, Huang GT, Yang PM, et al (1990). Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatol, 11, 481-8.   DOI
94 Triolo M, Corte CD, Colombo M (2014). Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int, 34, 139-5.   DOI
95 Zhu AX, finn RS, Mulcahy M, et al (2013). A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res, 19, 6614-3.   DOI
96 Zoutendijk R, Reijnders JG, Zoulim F, et al (2013). Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 62, 760-5.   DOI
97 Zhu AX, Kudo M, Assenat E, et al (2014). EVOLVE-1 Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol, in press.
98 Trevisani F, D'Intino PE, Morselli-Labate AM, et al (2001). Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol, 34, 570-5.   DOI
99 Tateishi R, Yoshida H, Matsuyama Y, et al (2008). Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int, 2, 17-30.   DOI
100 Villanueva A, Minguez B, Forner A, et al (2010). Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med, 61, 317-28.   DOI
101 Wogan GN (1992). Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res, 52, 2114-8.
102 Wang RT, Koretz RL, Yee HF Jr (2003). Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med, 115, 554-9.   DOI
103 Wilhelm SM, Carter C, Tang L, et al (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-109.   DOI
104 Wurmbach E, Chen YB, Khitrov G, et al (2007). Genomewide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatol, 45, 938-7.   DOI
105 Wong VW, Chan SL, Mo F, et al (2010). Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol, 28, 1660-5.   DOI